

行政院國家科學委員會專題研究計畫 期中進度報告

第二型環氧酵素(COX-2)基因對於非小細胞肺癌之醣化酵素
基因與 Lewis 涎化抗原表現之調控(1/3)

計畫類別：個別型計畫

計畫編號：NSC92-2314-B-002-294-

執行期間：92年08月01日至93年07月31日

執行單位：國立臺灣大學醫學院內科

計畫主持人：余忠仁

報告類型：精簡報告

處理方式：本計畫可公開查詢

中 華 民 國 93年6月21日

行政院國家科學委員會補助專題研究計畫 成 果 報 告
 期 中 進 度 報 告

第二型環氧酵素(COX-2)基因對於非小細胞肺癌之醣化酵素 基因與 Lewis 涎化抗原表現之調控(1/3)

計畫類別： 個別型計畫 整合型計畫

計畫編號：NSC92-2314-B-002-294

執行期間：92年08月01日至93年07月31日

計畫主持人：余忠仁

共同主持人：

計畫參與人員：

成果報告類型(依經費核定清單規定繳交)： 精簡報告 完整報告

本成果報告包括以下應繳交之附件：

赴國外出差或研習心得報告一份

赴大陸地區出差或研習心得報告一份

出席國際學術會議心得報告及發表之論文各一份

國際合作研究計畫國外研究報告書一份

處理方式：除產學合作研究計畫、提升產業技術及人才培育研究計畫、
列管計畫及下列情形者外，得立即公開查詢

涉及專利或其他智慧財產權， 一年 二年後可公開查詢

執行單位：國立台灣大學醫學院內科

中 華 民 國 九 十 三 年 六 月 十 六 日

一、中文摘要

關鍵詞：肺癌、醣化酵素基因、Lewis 涎化抗原、第二型環氧酵素

癌細胞之醣化過程異於正常細胞，特殊之醣化抗原(如 Lewis 涎化抗原)表現有利其脫離源發病灶，入侵血管，並逃避宿主之免疫系統攻擊。在吾人先前之研究中，已證實肺癌之異常醣化過程(Lewis 涎化抗原之產生)均與肺癌病患術後之預後有關，而利用 multiplex PCR 探討肺癌之醣化酵素基因表現(包括 sialyltransferase, STs; 與 fucosyltransferase, FucTs), ST3GalIII、FucTIII、IV、VI、VII 之表現量與 Lewis 涎化抗原之產生及肺癌之遠處轉移、術後存活有明顯相關。細胞株之研究亦顯示侵犯力高易轉移的細胞株 (CL₁₋₅, CL₁₋₅ F4), 其 STs 與 FucTs 之表現量高於侵犯力弱的母細胞株 (CL₁₋₀、CL₁₋₁)。而此一系列之細胞株呈現次第增加的第二型環氧酵素表現量。第二型環氧酵素被認為與腫瘤生長、反細胞凋亡、血管生成、細胞移動與侵犯能力有關，有初步證據證實再大腸癌細胞，第二型環氧酵素基因可以藉由調控某些醣化酵素基因而表現出 Lewis 涎化抗原，促進癌細胞轉移。其調控機轉至今仍無相關文獻探討。本三年研究計劃之目的為：(1)廣泛而完整的探討第二型環氧酵素基因與其產物(前列腺素，尤其是 PGE₂, PGI₂)之受體(EP1-4; PPAR α , γ , δ)在肺癌之表現情形以及與醣化酵素基因、以及 Lewis 涎化抗原表現之相關聯性；(2)對於由(1)所選出具臨床意義之 EP, PPAR 受體與醣化酵素基因，本研究將著手探討第二型環氧酵素對這些醣化酵素基因表現之訊息傳遞調控機轉。

英文摘要

Keywords : Lung cancer, glycosyltransferase, sialyl Lewis antigen, cyclooxygenase-2

Products of aberrant glycosylation may facilitate tumor cell invasion into blood stream, attachment to endothelial cells and escape from host immuno-surveillance. Our previous studies had demonstrated the prognostic implication of sialyl Lewis antigens (sLe^x and sLe^a) for lung cancer. Lung cancers overexpressing sLe antigens tend to have higher chance of recurrence and metastasis. Using multiplex PCR to evaluate the expression of sialyltransferase(ST) and fucosyltransferase(FucT) gene families in lung cancer, we have demonstrated that tumors with overexpression of ST3GalIII and FucTIII, IV, VI, VII are closely related to expression of sialyl Lewis antigens, and to cancer recurrence and postoperative death. Cell line study revealed that cell lines (CL₁₋₅, CL₁₋₅ F4) with high invasiveness and metastasis ability expressed more STs and FucTs than parent cell line (CL₁₋₀ and CL₁₋₁). This panel of cell lines possess incremental expression of cyclooxygenase-2 (COX-2), positively correlate with the degree of invasiveness. COX-2 involves many aspects of cancer cell biology, including cell growth, antiapoptosis, angiogenesis, cell motility and invasion. Evidence has been demonstrated in colon cancer cell lines that, COX-2 can promote cancer metastasis through expression of certain glycosyltransferase genes and sialyl Lewis antigens. Up to now, the mechanisms of how COX-2 regulate the expression of GT genes has never been reported. We thus propose a three-year study to comprehensively study the expression of COX-2, the receptors of COX-2 products (i.e., prostaglandins, PG), EP1-4 and PPAR α , γ , δ in lung cancer. And correlate with expression status of GT genes and sLe antigens completed in our previous work. The study will identify specific glycosyltransferase genes, and, probably specific EP or PPAR related to COX-2 expression. The regulatory mechanism of COX-2 on these GT genes will then be explored.

二、緣由與目的

Cyclooxygenase is the enzyme catalyzing the rate-limiting step in prostaglandin synthesis, converting arachidonic acid(AA) into prostaglandin(PG) H₂. Two isoforms of this enzyme have been identified. Cyclooxygenase-1 (COX-1) is constitutively expressed in many tissues and plays roles in tissue homeostasis. In most cells and tissues, cyclooxygenase-2 (COX-2) is an inducible isoform whose expression is stimulated by growth factors, cytokines, and tumor promoters (1-3).

Mounting evidence documents elevated expression of COX-2 in a variety of malignancies including colon, gastric, esophageal, prostate, pancreatic, breast and lung carcinomas (4-13). Overexpression of tumor COX-2 may be important in tumor invasion (14,15), angiogenesis (16-19), resistance to apoptosis (20-22), and suppression of host immunity (13, 23). Recently, the importance of COX-s expression in lung cancer had been demonstrated by a variety of reports (24-29).

Elevated expression of COX-2 has been shown to increase tumor invasiveness and enhance metastatic potential (4, 30). The complex events associated with tumor cell invasion include the active movement of cells across the extracellular matrix and spread to distant organ sites (31). Overexpression of COX-2 in cancer cells increased cell adhesion to the extracellular proteins laminin and Matrigel (20, 30). The biochemical changes associated with these altered cellular dynamics include increased expression and activation of matrix metalloproteinase-2 (MMP2), and reduced expression of E-cadherin (20, 30). In coherence, COX-2 inhibitors have been found to reduce tumor cell migration, cell adhesion, and tumor invasiveness in in vivo and in vitro experimental systems. These effects were observed in various cancer cells including liver, prostate, colon and breast (32-35). A recent study in non-small cell lung cancer cell lines concluded that cell invasiveness promoted by COX-2 is mediated by the cell surface receptor for hyaluronate, CD44 (36). Overexpression of COX-2 caused cell invasiveness and also increased CD44 expression. Moreover, cell invasion was significantly reduced in cells overexpressing COX-2, but where CD44 was specifically blocked. In colorectal carcinoma cells, the phosphatidylinositol-3-kinase/ Akt kinase/protein kinase B pathway was recently found to mediate PGE₂-promoted cell motility (37). Based on these results, there are likely to be multiple, cell-type dependent mediating pathways for COX-2 promoted cell invasion.

More recently, investigators had demonstrated the interaction between between COX-2 activity and the expression of sialyl Lewis antigens, the cancer-associated carbohydrate antigens.closely related to hematogeneous metastasis of colon, breast and lung cancer, and the expression of enzymes synthesizing sialyl Lewis antigens (15). Effects of COX-2 activity and prostaglandin E₂ on cell adhesion, expression of sialyl Lewis antigens, and glycosyltransferase(GT) genes were determined in Caco-2-m cells (a colon cancer cell line expressed COX-2 low level), Caco-2-COX-2 (Caco-2 programmed to overexpress COX-2), and HT-29 cells (a colon cancer cell line with high level of COX-2). Caco-2-COX-2 cells had increased SPan-1 levels and increased adherence to endothelial cells via SPan-1 compared with Caco-2-m cells. HT-29 cells expressed sialyl Lewis a (sLe^a) and adhered to endothelial cells via sLe^a. Treatment with a COX-2 inhibitor, celecoxib, decreased SPan-1 and sialyl Lewis a expression and adherence to endothelial cells. Caco-2-COX-2 and HT-29 cells metastasized to the liver, whereas Caco-2-m cells did not. Pretreatment with celecoxib reduced the metastatic potential, and inhibit the

expression of three GTs synthesizing sLe^a antigen, β 3Gal-T5 and ST3Gal III and IV. The study indicate a direct link between COX-2 and enhanced adhesion of carcinoma cells to endothelial cells, and enhanced liver metastatic potential via accelerated production of sialyl Lewis antigens. COX-2 inhibitors may suppress metastasis. However, they didn't establish a similar correlation or consequences in clinical settings.

Despite tremendous progress made in understanding the functional role of COX-2 in cell growth, cell death, cell motility, and in cancer, the complete picture of downstream signaling pathways for the various effects of COX-2 is not yet understood. Prostaglandins (PGs) have been shown to play roles in the wide spectrum of biological processes related to COX-2. PGH2 is an unstable endoperoxide intermediate, which subsequently is converted to one of several structurally related eicosanoids, including PGD2, PGF2 α , PGI2, and thromboxane A2, by the activity of specific cellular PG synthases.

PGE2 is constitutively produced by many cancers, including nons-small cell lung cancer (38). PGE2 elicits its effects on target cells through interaction with prostaglandin E series receptors (cell surface G-protein-coupled eicosanoid receptors) of four distinct subtypes, designated EP1, EP2, EP3, and EP4 (39). Signaling downstream from the different EP receptors varies, probably because each receptor interacts with different G proteins. EP1 causes influx of Ca²⁺ and activation of protein kinase C; receptors EP2 and EP4 activate adenylate cyclase, which increases cellular cyclic AMP levels and activates protein kinase A; and EP3 signals primarily through an inhibitory G protein to decrease intracellular cyclic AMP levels. Growth-promoting effects are signaled via EP receptors in several cell types. In primary keratinocytes, growth promotion was signaled via an EP2 and/or EP4 receptor-cAMP coupled response (40). As mentioned beforehand, in a recent study in colorectal carcinoma cells, PGE2 promoted cell growth and motility via the EP4 receptor by activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt/PKB) pathway (37). Similarly, the effect of PGE2 in mediating the expression of CD44 and MMP2 in lung cancer was recently shown to work through the EP4 receptor (41). Interestingly, EP2 and EP3 were also expressed in the colon and lung carcinoma cells (41, 42) and their binding affinities to PGE2 are similar to EP4. It is currently not understood how growth and motility signaling was selectively directed to the EP4 receptor.

The classical signaling pathway of PGI2 uses a G-protein-coupled cell surface receptor termed IP (43). Researches had demonstrated PGI2-IP signaling is indeed important in preventing thrombosis and is involved in inflammatory responses (44), but nothing related to tumorigenesis. Peroxisomal proliferator-activated receptors (PPARs), PPAR α , PPAR γ , PPAR δ , though initially cloned as a family of orphan receptors, are now known to mediate downstream signaling of nuclear PG, including PGI2. PPARs bind to sequence-specific DNA response elements (PPRE) as a heterodimer with the retinoic acid receptor (RXR) (45). Although the identity of definitive high-affinity natural ligands for PPARs is lacking, there is evidence that AA metabolites can serve as activating ligands for PPARs. In particular, the PGD2 metabolite, 15-deoxy 12,14 PGJ2 is a potent activator of the PPAR γ isoform (46, 47), whereas a stable analog of PGI2, carbaprostacyclin (cPGI), has been shown to activate PPAR δ and to a much lesser extent, PPAR α .(48,49) Research on PPARs has revealed that the PPAR α and PPAR γ isoforms play fundamental roles in such diverse physiological processes as lipid metabolism, immunity, and

cellular differentiation (50,51). There also has been a great deal of interest in PPARs and cancer. Activators of PPAR α will induce the formation of hepatocellular carcinomas in rodents (52), whereas ligands for PPAR γ have been shown to induce cellular changes consistent with differentiation and reversal of the neoplastic phenotype in liposarcoma (53), breast (54), and colon carcinoma cells (55). In addition, inactivating mutations in PPAR γ recently were identified in a subset of colorectal tumors, strongly suggesting that this isoform has a tumor suppressive role during colorectal carcinogenesis (56). Recently, PPAR δ was shown to be aberrantly expressed in colorectal cancers, and that endogenous PPAR δ is transcriptionally responsive to PGI₂ (57). It is also interesting to note that co-overexpression of COX-2 and PPAR δ has also been reported in endometrial adenocarcinoma (58). However, the functional consequence of PPAR δ activation in carcinogenesis still needs to be determined. So far, all researches investigating PPARs expression in lung cancer have focused on PPAR γ and clearly suggested PPAR γ plays a tumor suppressor role in lung cancer (59-61). No reports had been made regarding the expression of the other PPARs (PPAR α , and PPAR δ) and their association with COX-2 gene expression in lung cancer. The following experiments will be carried out to establish the potential relationship between the expression of COX-2 and the expression of specific GT genes and to elucidate the regulatory mechanism of COX-2 on specific GT gene.

1. Real-time quantitative RT-PCR to measure the expression of COX-2, EP (EP1, EP2, EP3, EP4) and PPAR (PPAR α , γ , δ) genes in tissues of non-small cell lung cancer, as well as in CL cell lines. The data will be matched with the expression status of GT genes and sLe antigens available from our previous study. This will demonstrate the association among COX-2, its specific receptors (especially EP4 and PPAR- δ) and GTs (especially FucT III-VII, and ST3GalIII) genes and sLe antigens.
2. We will establish cell line from CL₁₋₀ with stable transfection of human COX-2 cDNA with inducible overexpression system for studying COX-2 signaling pathway related to GT genes expression in lung cancer cells. The pharmacological effect of COX-2 inhibitor, PGE₂, EP agonist/antagonist, PPAR agonist/antagonist on cell migration, invasion, and adhesion to HUVEC and ECM, GT expression, sialyl Lewis antigens expression will be performed.

三、材料與方法

Lung cancer tissues

Surgical specimens of tumors and the adjacent uninvolved lung tissue will be obtained from patients with lung cancer at the time of resection. All patients should have non-small cell lung cancer confirmed by histological diagnosis. All patients have been judged preoperatively to have resectable disease, and all undergo a complete resection of the tumor. After excision, tumor samples and the uninvolved lung tissues were collected immediately, snap frozen in isopentane at -60°C placed in sterile jar and stored at -70°C until processed. Specimens used for formalin fixation and for OCT embedding are collected separately from specimens used for RNA isolation. The resected lung and lymph nodes were subjected to routine surgical pathological examination. Representative sections required for staging and histologic classification were generously taken. Sections of $4\mu\text{m}$ thickness were routinely stained with hematoxylin-eosin. Histologic classification was based on World Health Organization criteria. The final staging of each patient

was pathologic, according to the international staging system for lung tumors. The 74 pairs of lung tumor/nontumor lung tissues used in previous studies were applied to investigation. There were 42 adenocarcinomas, 26 squamous cell carcinomas, 3 large cell carcinomas, and 3 adenosquamous carcinoma. The gender distribution was: 48 men and 26 women. The mean age was 61.3 ± 11.4 years old, range from 24.1 to 78.2 years old. Cigarette smoking was more prevalent in male patients (37 patients, 71.2%) than in female patients (4 patients, 15.4%). The distribution of pathological stage was: 37 stage I disease (11 stage IA and 26 stage IB), 17 stage II (2 stage IIA and 15 stage IIB), and 20 stage IIIA. T stage distribution was: 14 T1, 50 T2, 10 T3. N stage distribution was: 43 N0, 15N1, 16N2. Tumor recurrence developed in 44 patients in a mean duration of 11.8 ± 11.7 months (range from 2 to 50 months, median 9 months), 32 had recurrence due to distant metastasis (17 brain, 13 bone, 7 contralateral lung, 5 liver, and 2 pericardium). Thirty-three patients died 11.8 ± 19 months (range from 5-51 months, median 19 months) after operation. The follow-up period for the survived patients was 41.1 ± 29.3 months (median, 35 months), lasted till October 31, 2002.

Cell lines

A panel of human lung adenocarcinoma cell lines, CL₁₋₀, CL₁₋₁, CL₁₋₅, CL₁₋₅F4, in ascending order of invasiveness and metastasis, was established previously [30]. CL₁₋₀ is the parent cell line, while CL₁₋₁, CL₁₋₅ and CL₁₋₅F4 are sublines that were selected from CL₁₋₀ cultured with a polycarbonate membrane coated with Matrigel in Transwell invasion chamber. The cells that migrated through the membrane were harvested. The sublines from the first, and fifth rounds of selection were assigned CL₁₋₁, CL₁₋₅ and a further fourth round of selection of CL₁₋₅ was assigned CL₁₋₅F4. A549 cell lines stably transfected with COX-2 and anti-sense COX-2, as well as vector alone were given by Dr. Stewart Dubinnett from UCLA.

Real-time Quantitative RT-PCR for COX-2

The expression of COX-2 in tissues and cell lines, and GT genes in CL₁₋₀ or CL₁₋₅F4 were evaluated with real-time PCR. RNA samples were reverse transcribed using MgCl₂ (5.5 mM), dNTPs (0.5 mM each), random hexamers (1.25 μ M), oligodeoxythymidylic acid (1.25 μ M), RNase inhibitor (0.4 unit/ μ l), and multiscribe reverse transcriptase (1.25 units/ μ l), all from PE Biosystems (Warrington, United Kingdom). The mix was aliquoted into individual tubes (16 μ l/tube), and template RNA was added (4 μ l/tube of 250 ng/ μ l RNA). Samples were incubated for 60 min at 25°C, 45 min at 48°C, and then 5 min at 95°C. A reaction mix was made containing Taqman buffer (5.5 mM MgCl₂, 200 μ M dATP, 200 μ M dCTP, 200 μ M dGTP, 400 μ M dUTP); TBP (TATA Box binding protein, as internal control) forward and reverse primers and probe (all at 50 nM); forward and reverse primers for COX-2 (300 nM); probe (200 nM); AmpErase UNG (0.01 unit/ μ l); and AmpliTaq Gold DNA Polymerase (0.025 unit/ μ l), all from PE Biosystems. A volume of 48 μ l of reaction mix was aliquoted into separate tubes for each cDNA sample and 2 μ l/replicate of cDNA were added. After mixing, 23 μ l of sample were added to the wells on a PCR plate. Each sample was added in duplicate. A no-template control (containing water) was included in triplicate. Wells were sealed with optical caps, and the PCR reaction was run on an ABI Prism 7700 using standard conditions. COX-2 primers and probe for quantitative PCR were designed using the PRIMER express program (PE Biosystems). The sequences of the COX-2 primers and probe were as follows. Forward: 5'-ATGGAATTACCCAGTTTGTGAATC-3';

reverse: 5'-TGGAAGCCTGTGATACTTTCTGTACT-3'; probe (FAM labeled):
5'-TCCTACCACCAGCAACCCTGCCAT-3'.

Quantitation of multiplex RT-PCR of GT genes products

The expression of selected glyco-genes or gene family in tissues will be evaluated using multiplex PCR, which has been established in our previous study. CDNA is synthesized from the isolated total RNA by reverse transcription in 20 μ l reactions containing 0.5 μ g of random primers, 200 U of superscript RTse, 2 μ g of total RNA, 4 μ l of 5X RT buffer, 0.1mM each dNTP, 20 units Rnasin, and 6.5 μ l DEPCed water. Each tube is incubated at room temperature for 10 min and then at 42°C for 45min, heated to 90°C for 10 min, and then quick-chilled on ice. CDNA clones of each genes will be used as positive control. The PCR primers are designed based on the cDNA sequence of specific gene, and are selected with Primer 3 (a web-based primer designed, Whitehead Institute for Biomedical Research). In designing the primers for multiplex PCR, the possibility of primer dimerization is minimized by cross-examination of the mismatches in the sequences of each possible pair of all the primers chosen. Primers with optimal annealing temperatures of 56-60°C are chosen to prevent mismatches, and primers with higher temperatures are chosen for shorter PCR products. Each PCR is performed in a 100- μ l reaction mixture containing 10 μ l RT reaction mixture, 1X PCR buffer, 0.1mM of each dNTP, 2.5 units of *Taq* polymerase, adjusted concentration of each primers, and subjected to 28-30 cycles of PCR reaction. The PCR reaction products are then electrophoresed in a 3% agarose gel and stained with ethidium bromide, and the size of each cDNA product is determined by comparison to size marker (100bp DNA ladder). After amplification, the PCR products were electrophoresed in 3% agarose gel, stained in 5 μ g/ml ethidium bromide solution for 30 min, and then destained. The signal intensity of amplified native and mutated products was directly measured and digitized by IS-1000 digital imaging system (Alpha Innotech Incorp., San Leandro, CA). To evaluate the relative levels of expression of the target genes in multiplex RT-PCRs, the value of the internal standards (β 2-microglobulin, or GAPDH) in each test tube is used as the baseline gene expression of that sample, and the relative value is calculated for each of the target genes amplified in that reaction. These values are then used to compare expression across samples tested.

Detection of Lewis antigens by flow cytometry





Cells (1×10^6) are detached with 2 mmol/L EDTA, washed and resuspended in NaCl/Pi containing 1% BSA, the incubated with different mAbs to Lewis antigens (1:50 dilution) for 30 min at 4°C. After two washes, the cells are incubated for 45 min at 4°C with a 1:200 dilution of FITC labeled goat anti-Igs. Then the cells are subjected to fluorescence analysis performed on a FACScan.

四、結果

Previously, we have studied the expression of sialyl Lewis antigens (sialyl Lewis X, sLe^x and sialyl Lewis A, sLe^a) and the glycosyltransferases responsible for synthesizing both antigens in 74 non-small cell lung cancer tissues. The results revealed that Survival analysis demonstrated that patients bearing tumors with expression of sLe^a and sLe^x antigens tended to have shorter disease-free-survival and overall survival (Fig 1A, 1B, 1C, 1D).

Fig 1A. sLe^x staining


Fig 1B. sLe^a staining



Tumors with higher level of either sLe^a or sLe^x expression tend to have higher chance of brain metastasis ($P=0.048$ for 3+ sLe^x, and $P=0.017$ for 2+ and 3+ sLe^a), while high level of sLe^x was also correlated with lung metastasis ($P=0.038$).

While using multiplex PCR to quantify the mRNA expression of glycosyltransferase genes (Fuc-T III, IV, V, VI, VII and ST3Gal II, III, IV, V, VI), overexpression (defined as the expression ratio of specific gene is 1.5 fold higher than that in paired non-tumor lung tissue) of glycosyltransferase genes could be demonstrated in about half of lung cancer regardless of the histology. Correlation can be established between high level of sialyl Lewis antigen expression and overexpression of specific glycosyltransferase genes. High level of sLe^a antigen expression in lung cancer tissue correlated with overexpression of ST3Gal III ($P=0.028$), but not with FucT-III ($P=0.097$). High level of sLe^x antigen expression in lung cancer tissue correlated with overexpression of three fucosyltransferase genes: FucT-III ($P=0.009$), and FucT-VI ($P<0.001$). When comparing the expression of various glycosyltransferase genes with the pattern of tumor relapse, distant metastasis was related to overexpression of ST3Gal III ($P=0.048$), FucT-V ($P=0.037$), and FucT-VI ($P=0.01$). Brain metastasis was related to overexpression of FucT-IV ($P=0.007$), FucT-V ($P=0.008$), and FucT-VI ($P=0.009$).

By measuring the expression of COX-2 RNA in lung cancer, we have demonstrated that NSCLC with high level of COX-2 expression tended to have a worse prognosis (Fig.2), and the expression of COX-2 RNA was associated with the overexpression of FucT-VII ($P=0.003$).



cox 2 tumor relative to median * f7 ratio Crosstabulation

Count	f7 ratio		Total
	<1	>=1	
cox 2 tumor relative to median < -2.34	22	12	34
cox 2 tumor relative to median >=-2.34	11	26	37
Total	33	38	71

Fig. 2 COX-2 expression and survival of NSCLC

However, using COX-2 stable transfection with A549 cells (Fig. 3), the expression of sialyl Lewis antigens did not show significant change when compared with parent lines (Fig. 4 & Fig. 5).




Fig. 3 COX-2 RTQ-PCR in A549 cell lines




Fig. 4 SLe^a expression in transfected cell lines




Fig. 5 SLe^x expression in transfected cell lines

五、參考文獻

1. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. *Proc Natl Acad Sci USA*. 1996;93:4816-20.
2. Smith WL, Garavito RM, Dewitt DL. Prostaglandin E2 enhance endoperoxide H synthases (cyclooxygenases)-1 and -2. *J Biol Chem* 1996;271:33157-60.
3. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. *Biochem Biophys Acta* 2000;1470:M69-78.
4. Williams CS, Tsujii M, Reese J, Dey SK and DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. *J Clin Invest* 2000;105:1589-94.
5. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki, AT. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. *Cancer* 2000; 89: 2637-45
6. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. *Carcinogenesis* 2000;21:139-46
7. Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN. Regulation of Constitutive Cyclooxygenase-2 Expression in Colon Carcinoma Cells. *J Biol Chem*. 2000;275: 33951-6
8. Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu X, Levine AC. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. *Urology* 2000; 56, 671-6
9. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, Yano M, Inoue M, Matsuura N, Shiozaki H, Monden M. Up-Regulation of Cyclooxygenase-2 in Squamous Carcinogenesis of the Esophagus. *Clin Cancer Res* 2000; 6:1229-38
10. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased Cyclooxygenase-2 Expression in Human Pancreatic Carcinomas and Cell Lines. *Cancer Res*. 1999;59: 4356-62.
11. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ. Cyclooxygenase-2 Expression Is Up-Regulated in Squamous Cell Carcinoma of the Head and Neck. *Cancer Res*. 1999;59: 991-4
12. Dannenberg AJ, Zakim D. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. *Semin Oncol* 1999;26: 499-504
13. Huang M, Stolina M, Sharma S, Mao J, Zhu L, Miller P, Wollman J, Herschman H, Dubinett S. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. *Cancer Res*. 1998;58:1208-16
14. Niki T, Kohno T, Iba S, Moriya Y, Takahashi Y, Saito M, Maeshima A, Yamada T, Matsuno Y, Fukayama M, Yokota J, Hirohashi S. Frequent Co-Localization of Cox-2 and Laminin- 2 Chain at the Invasive Front of Early-Stage Lung Adenocarcinomas. *Am J Pathol*. 2002;160,

15. Kakiuchi Y, Tsuji S, Tsujii M, Murata H, Kawai N, Yasumaru M, Kimura A, Komori M, Irie T, Miyoshi E, Sasaki Y, Hayashi N, Kawano S, Hori M. Cyclooxygenase-2 Activity Altered the Cell-Surface Carbohydrate Antigens on Colon Cancer Cells and Enhanced Liver Metastasis. *Cancer Res* 2002; 62: 1567-72
16. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. *J Urol* 2000;164, 820-5.
17. Masferrer JL, Leahy KM, Koki AT. Role of cyclooxygenases in angiogenesis. *Curr Med Chem* 2000; 7:1163-70
18. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitors. *Cancer Res.* 2000;60:1306-11
19. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 Expression Is Related to Prostaglandin Biosynthesis and Angiogenesis in Human Gastric Cancer. *Clin Cancer Res.* 2000;6:135-8
20. Tsujii M, Dubois R. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. *Cell* 1995;83:493-501
21. Ding X Z, Tong WG, Adrian TE. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. *Anticancer Res.* 2000;20:2625-2631
22. Tanji N, Kikugawa T, Yokoyama M. Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 protein expression. *Anticancer Res.* 2000;20: 2313-19
23. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, Lee JC, Dubinett SM. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. *J Immunol* 2000;164:361-70
24. Hida T, Leyton J, Makheja A, Ben-Av P, Hla T, Martinez A, Mulshine J, Malkani S, Chung P, Moody T. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. *Anticancer Res.* 1998;18:775-82
25. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. *Cancer Res.* 1998;58: 4997-5001
26. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K-i, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. *Cancer Res.* 1998;58:3761-4
27. Watkins DN, Lenzo JC, Segal A, Garlepp MJ, Thompson PJ. Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. *Eur Respir J.* 1999;14:412-8
28. Ochiai M, Oguri T, Isobe T, Ishioka S, Yamakido M. Cyclooxygenase-2 (COX-2) mRNA

- expression levels in normal lung tissues and non-small cell lung cancers. *Jpn J Cancer Res.* 1999;90:1338-43
29. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. *Clin Cancer Res* 2000;6:2006-11
 30. Tsujii M, Kawano S, DuBois R. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. *Proc Natl Acad Sci USA.* 1997;94, 3336–40
 31. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. *Cancer Res.* 1995;55:1856-62.
 32. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. *Cancer Res* 2000;60: 4629-37.
 33. Jiang MC, Liao CF, Lee PH. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. *Biochem Biophys Res Commun* 2001;282: 671-7.
 34. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. *Int J Cancer* 2001;91: 894-9.
 35. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. *Int J Cancer* 2001;93: 497-506.
 36. Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty G, Sharma S, Huang M, Pold M, Batra R, Dubinett S. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. *J Biol Chem.* 2001;276:20809-12.
 37. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. *J Biol Chem* 2001;276:18075-81.
 38. Casibang M, Purdom S, Jakowlew S, Neckers L, Zia F, Ben-Av P, Hla T, You L, Jablons DM, Moody TW. Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. *Lung Cancer.* 2001;31:203-12.
 39. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: Subtypes and signaling. *Annu Rev Pharmacol Toxicol* 2001;41: 661-90.
 40. Konger RL, Malaviya R, Pentland AP. Growth regulation of primary human keratinocytes by prostaglandin E receptor EP2 and EP3 subtypes. *Biochim Biophys Acta* 1998;1401: 221-34.
 41. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S, Dubinett SM. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. *J Biol Chem* 2002;277:50828-33

42. Yano T, Zissel G, Muller-Qernheim J, Shin SJ, Satoh H, Ichikawa T. Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. *FEBS Letters* 2002;518:154-8.
43. Namba T, Oida H, Sugimoto Y, Kakizuka A, Negishi M, Ichikawa A, Narumiya S. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. *J Biol Chem* 1994;269:9986-92.
44. Baxter GS, Clayton JK, Coleman RA, Marshall K, Sangha R, Senior J. Characterization of the prostanoid receptors mediating constriction and relaxation of human isolated uterine artery. *Br J Pharmacol* 1995;116:1692-6.
45. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. *Proc Natl Acad Sci USA* 1994;91:7355-9
46. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. *Cell* 1995;83: 813-9
47. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. *Cell* 1995;83:803-12 .
48. Lim H, Gupta RA, Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM, Dey SK. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. *Genes Dev.* 1999;13: 1561-74
49. Forman BM, Chen J, Evans RM.. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. *Proc Natl Acad Sci USA* 1997;94:4312-7.
50. Kliewer SA, Lehmann JM, Milburn MV, Willson TM. The PPARs and PXR: nuclear xenobiotic receptors that define novel hormone signaling pathways. *Recent Prog Horm Res.* 1999;54:345-67 .
51. Lim H, Dey SK. A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. *Endocrinology* 2002;143:3207-10.
52. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. *Carcinogenesis* 1997;18:2029-2033 .
53. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiock S, Oppenheim H. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. *Proc Natl Acad Sci USA* 1997;94:237-41
54. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. Terminal differentiation of human breast cancer through PPAR gamma. *Mol Cell* 1998;1: 465-70 .

55. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. *Nat Med* 1998;4:1046-52 .
56. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C. Loss-of-function mutations in PPAR gamma associated with human colon cancer. *Mol Cell* 1999;3,799-804.
57. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. *Proc Natl Acad Sci USA* 2000;97:13275-80.
58. Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, DuBois RN, Dey SK. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. *Neoplasia* 2000;2:483-90.
59. Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, Heasley LE, Nemenoff RA. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. *Mol Pharmacol.* 2002;62:1207-14.
60. Satoh T, Toyoda M, Hoshino H, Monden T, Yamada M, Shimizu H, Miyamoto K, Mori M, Yamada M, Mori M. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. *Oncogene.* 2002;28;21:2171-80.
61. Sasaki H, Tanahashi M, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y. Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. *Lung Cancer.* 2002;36:71-6.